Convalife Pharmaceuticals Licenses Karus Therapeutics’ CVL237 Globally
Shanghai-based Convalife Pharmaceuticals has entered into a licensing agreement with UK-based Karus Therapeutics Ltd, acquiring...
Cancer
HutchMed Initiates China Bridging Study for Tazverik in Follicular Lymphoma
HutchMed (NASDAQ: HCM, HKG: 0013) announced the initiation of a bridging study for Tazverik (tazemetostat)...
HutchMed’s H1 2022 Oncology Sales Surge 82% on Strong Product Performance
China-based biopharma HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) reported strong financial results for the...
OriginCell Therapeutics Raises USD 120M in Series B for Tumor Immunotherapy Pipeline
OriginCell Therapeutics, a Shanghai-based tumor immunotherapy specialist, reportedly raised over USD 120 million in a...
GluBio Pharma Raises USD 22M in Series A+ Round to Advance TPD Pipeline
GluBio Pharmaceutical Co., Ltd, a Zhejiang-based specialist in molecular glue targeted protein degradation (TPD), reportedly...
Sanjin Pharma’s Subsidiary Gets FDA Nod for BC007 Cancer Drug Trial
China-based Guilin Sanjin Pharmaceutical Co. Ltd (SHE: 002275) announced that its subsidiary, Dragon Boat Pharmaceutical...
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...
Dongcheng Pharmaceutical Gets NMPA Green Light for PSMA PET Imaging Drug
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced it has received approval from...
CSPC Pharmaceutical’s Albumin-Bound Docetaxel Receives Orphan Drug Designation for Gastric Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received an orphan drug...
Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors
Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...
Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review
Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...
CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment
China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...
Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...
Lepu Biopharma’s Pucotenlimab Receives Conditional NMPA Approval for MSI-H/dMMR Tumors
The National Medical Products Administration (NMPA) has granted conditional market approval to Lepu Biopharma Co.,...